Numinus Wellness Inc (TSXV: NUMI) operates as a healthcare firm that provides psychological treatments and solutions for mental illness.
It offers therapies for depression, PTSD & substance use disorders. In Montreal, the healthcare firm provides Ketamine-assisted psychotherapy to heal depression. It offers wellness solutions by delivering innovative mental health care and provides safe, evidence-based psychedelic-assisted therapies.
Numinus Wellness partners with practitioners to support its patients and develop psychedelic-assisted psychotherapy.
The company operates through Salvation Botanicals and Numinus Health.
The company through clinics and virtual services delivers treatment related to various diseases, including physical, mental, emotional health, anxiety, depression and mental trauma.
It offers safe, accessible, and evidence-based psychedelic-assisted psychotherapies in British Columbia, Canada. In addition, it claims to have a license by Health Canada related to substance and controlled drugs. With this license, the firm claims to engage assembly, export, possession, production, and sale of various psychedelic compounds, including DMT, Psilocin, Ketamine, Psilocybe mushroom extracts, LSD, Psilocybin, MDMA, and Mescaline.
The company offers training, resources and facilities to medical leaders and practitioners in psychedelic and mental health programming centers. In addition, it also provides healing and wellness solutions.
The company initially operated out of a Vancouver-based clinic and over the claims to have expanded nationally. It acquired Montreal-based Mindspace Wellbeing.
Numinous Wellness offers Ketamine-assisted psychotherapy for treatment of depression, anxiety, and trauma at Drive and Mindspace clinic. The Drive is a Vancouver-based mental health and wellness clinic.
In addition, the firm offers counselling services, psychotherapy, and psychedelic integration services.
Mindspace, a Montreal-based center, offers services to improve psychological health and empower well-being.
In December 2020, Numinus Wellness Inc and MAPS Public Benefit Corporation (Multidisciplinary Association for Psychedelic Studies) collaborated to offer MDMA-assisted psychotherapy. The treatment is given to patients who are experiencing posttraumatic stress disorder (PTSD) around the world.
On November 18, 2020, Numinus Wellness Inc declared a compassionate access clinical trial for psilocybin-assisted psychotherapy to treat substance use disorders. In collaboration with Syreon Corporation, the company aims at treating substance use disorders. Syreon Corporation is engaged in several clinical trials related to chronic and complex diseases.